Mounjaro vs Wegovy comparison graphic with split teal and grey background, molecular icons, flame and fork symbols, and bold title ‘The Science, Hormones, and Results Behind the Top Weight Loss Medications’ with TribElle branding.

GLP1s Women's weight loss UK Tirzepatide UK

NICE Classifies Obesity as Chronic: GLP-1 Implications

J Boora

June 25, 2026

Obesity Is Now Recognised as a Chronic Disease

In the UK, the National Institute for Health and Care Excellence (NICE) recognises obesity as a chronic, relapsing disease requiring structured medical management rather than short-term behavioural intervention.

This classification reflects modern understanding that obesity is driven by:

Dysregulated appetite signalling
Neurohormonal adaptation
Genetic susceptibility
Metabolic adaptation favouring weight regain

Obesity is not simply excess adiposity. It is a state of altered biological regulation.

Like hypertension or type 2 diabetes, it typically requires ongoing treatment.

What Does "Chronic" Mean in Clinical Terms?

A chronic condition is one that:

Persists long term
Has underlying pathophysiology
Tends to relapse without treatment
Requires sustained management

We do not "cure" hypertension. We manage it.

We do not prescribe antihypertensives for six months and expect blood pressure to remain permanently controlled.

The same principle now applies to obesity.

The Biological Defence of Body Weight

Body weight is regulated around a defended "set point", mediated through:

Hypothalamic appetite pathways
GLP-1 signalling
Leptin resistance
Reward circuitry
Energy expenditure adaptation

When weight is reduced through calorie restriction alone, the body compensates by:

Increasing hunger hormones
Reducing resting metabolic rate
Enhancing reward response to food

This biological resistance explains high relapse rates following diet-only interventions.

Where GLP-1 Medications Fit Into Chronic Disease Management

In the UK, GLP-1 receptor agonists such as:

Wegovy
Mounjaro

are prescribed for chronic weight management under specific eligibility criteria.

These medications act centrally and peripherally to:

Reduce appetite
Slow gastric emptying
Improve satiety signalling
Modulate reward pathways

They do not simply "reduce calories". They modify the biological drivers of obesity.

What the Evidence Shows About Long-Term Use

Semaglutide: STEP Programme

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) demonstrated:

~15% mean weight loss at 68 weeks
Significant reductions in appetite
Improved cardiometabolic risk markers

However, the STEP 4 withdrawal study showed that when semaglutide was stopped:

Participants regained two-thirds of lost weight within one year

This strongly supports obesity as a chronic, relapsing condition requiring continued treatment.

Tirzepatide: SURMOUNT Programme

The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) reported:

Up to 22.5% mean weight loss
Significant improvements in blood pressure, lipid profiles and glycaemia

Emerging data similarly suggest weight regain occurs after discontinuation.

The pharmacological effect persists only while treatment continues, as with antihypertensives.

The Hypertension Analogy

Consider blood pressure medication:

Elevated blood pressure reflects dysregulated vascular tone and neurohormonal signalling.
Medication restores physiological balance.
When stopped, blood pressure rises again.

No clinician interprets this as "treatment failure".

Similarly:

GLP-1 therapy reduces appetite dysregulation.
When stopped, underlying biological drivers return.

Weight regain does not mean the medication "stopped working".
It means the disease remains active.

Is Ongoing Appetite Suppression a Sign the GLP-1 Is Working?

Yes.

Reduced hunger, diminished food preoccupation ("food noise"), and earlier satiety indicate:

Effective GLP-1 receptor activation
Central appetite modulation
Reduced hedonic drive

These are clinical markers of therapeutic response.

Weight loss itself is a downstream effect of hormonal normalisation.

NICE Guidance and UK Clinical Practice

NICE obesity guidance supports pharmacological therapy as part of:

Specialist weight management pathways
Structured behavioural intervention
Ongoing medical supervision

Increasingly, UK clinicians recognise that for many patients:

Long-term pharmacotherapy may be appropriate, analogous to chronic cardiovascular management.

The framing is shifting from short-term "weight loss treatment" to long-term metabolic disease management.

Common Questions in UK Practice

"Should I stop once I reach my goal weight?"

From a chronic disease perspective, discontinuation often results in relapse.

Dose adjustment or maintenance strategies may be appropriate, but abrupt cessation without a plan increases risk of regain.

"Does needing long-term medication mean I've failed?"

No.

Needing treatment reflects biology, not character. We do not interpret the need for lifelong levothyroxine as a moral failing. Nor should we do so with obesity.

The Cardiometabolic Implications

Beyond weight reduction, GLP-1 therapies improve:

Blood pressure
Glycaemic control
Lipid profiles
Inflammatory markers

Long-term cardiovascular outcome data for Semaglutide show reduced major adverse cardiac events in high-risk populations. Lincoff et al., NEJM 2023

Thus, the rationale for continuation extends beyond aesthetic weight reduction.

The Clinical Reality

Obesity is:

Chronic
Relapsing
Neurohormonally driven

GLP-1 medications:

Restore regulatory balance
Reduce pathological hunger
Lower defended weight set point

Stopping treatment removes that regulatory support.

Executive Summary

Is obesity a chronic disease according to NICE?

Yes. NICE recognises obesity as a chronic condition requiring long-term management.

Do GLP-1 medications need to be taken long term?

For many patients, yes, similar to blood pressure medication.

Does weight regain after stopping GLP-1 mean it failed?

No. It reflects reactivation of the underlying disease process.

Is reduced appetite a sign GLP-1 is working?

Yes. Appetite suppression indicates effective receptor activity.

Final Clinical Perspective

The shift in UK medicine is conceptual as much as pharmacological.

We are moving from:

"Why can't patients maintain weight loss?"

"How do we sustainably manage a chronic metabolic disease?"

GLP-1 therapies represent a mechanistic intervention into appetite regulation.

For appropriately selected UK patients, continuation should be viewed not as dependency, but as disease control.

Just as we would not withdraw antihypertensive therapy in a patient whose blood pressure has normalised, we should not reflexively withdraw GLP-1 therapy in a patient whose metabolic regulation has improved.

Obesity management is entering its era of long-term medicine.

How Can TribElle Help?

We're not here to sell you a dream. We're here to back you up with:

Expert consultations with female-led clinicians who understand the mental and hormonal load.

Safe prescriptions with support every step of the way - including choosing between Wegovy and Mounjaro.

Ongoing check-ins, supplement guidance, and reorder options that don't make you jump through hoops.

And if you're still unsure? That's okay. Your body, your timeline.

Join the conversation